Patients with hemophilia B have seen their symptoms controlled for up to a year with a single dose of a gene therapy developed by Spark Therapeutics, almost entirely eliminating the need for treatment with clotting factors.

Results from the phase 1/2 trial of the Pfizer-partnered therapy have been hailed as an “important milestone” for patients with hemophilia B and evidence of a “renaissance” in gene therapy.